Ross Burns - Bioprocess Development Forum

Articles Downstream

September 5, 2024

Automation Downstream Controls Quality

Automation in bio/pharmaceutical manufacturing offers a reduction in human intervention, which can enhance quality in…

Ross Burns

Articles BioPharma Downstream

September 5, 2024

Developing a sterilizing grade filter for high concentration biologics

With the development and manufacture of subcutaneous biologics come challenges in the sterilizing or bioburden…

Ross Burns

Articles Downstream

August 22, 2024

Introducing Supor Prime Filters: A Filtration Solution for High-Concentration Therapies

The advent of new therapies brings new manufacturing challenges for biopharma. As an example, subcutaneous…

Ross Burns

Articles Downstream Downstream Multimedia

August 22, 2024

Download the infographic about viral vector manufacturing

Crafting a downstream viral vector process that's budget-friendly and GMP-ready is no small feat. But…

Ross Burns

Articles Downstream

August 22, 2024

Regulatory considerations for virus filtration process development

Virus filtration is a robust mechanism to ensure virus safety of biotherapeutic manufacturing processes and…

Ross Burns

Articles Downstream

August 22, 2024

Buffer optimization for bsAb separation in a capture step using MabSelect™ VL protein L resin

Protein L resins bind to the antibody kappa light chain and can be used for…

Ross Burns

Articles Downstream

August 13, 2024

A high-throughput study of sodium hydroxide cleaning efficiency for protein A resin

Cleaning-in-place (CIP) of chromatography resins is important for the integrity and safety of the final…

Ross Burns

Articles BioPharma

August 9, 2024

Streamlining Bioprocesses with Automation

Automation technologies used in the development and manufacture of biopharmaceuticals continue to evolve, provi

Ross Burns

Articles Upstream

August 8, 2024

Under pressure: exploring root causes of leaks in single-use mixers

Single-use technology offers huge benefits for both flexibility and efficiency. It reduces downtime by eliminating

Ross Burns

Articles Regulatory

August 8, 2024

Address the complexity of protein characterization

Since the FDA approved the first monoclonal based therapy in 1985, mAbs have had significant…

Ross Burns